MAY 15, 2019 12:00 PM EDT

Unraveling the legacy and future of Hepatitis B Diagnosis: Clinical impact of conventional molecular tests and HBV-RNA to monitor hepatic infections

Sponsored by: Abbott Molecular
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Head of Infectious Disease Research Abbott Diagnostics
    Biography
      Gavin A. Cloherty, Ph.D., is head of Infectious Disease Research for Abbott's diagnostics business. He provides scientific leadership in the area of infectious disease diagnostics by conducting groundbreaking clinical studies on hepatitis and HIV and developing new tests. As one of the top experts in the field, his innovative research is changing the way infectious diseases are being diagnosed to help improve patient outcomes.
      Gavin has more than 20 years of experience with Abbott and leads a team of scientists in the study of the viral diversity of HIV and hepatitis. His expertise is sought after globally through his established partnerships with commercial organizations, ministries of health, government agencies and academic institutions, such as the Centers for Disease Control and Prevention (CDC) and National Institutes of Health's AIDS Clinical Trial Group (ACTG) and Hepatitis B Research Network (HBRN). He has worked with the Republic of Georgia to help eradicate hepatitis C in the country, and is looking to expand these efforts to other regions of the world severely impacted by this disease.
      As a senior research scientist, Gavin assisted in the development and design of the Abbott Molecular RealTime tests and m2000 system. Throughout his career Gavin has published numerous studies, abstracts and posters. In addition to his impressive list of publications he also has been invited to speak at conferences around the world. Gavin graduated from the National University of Ireland, Galway, where he received his Ph.D. in molecular biology and a Bachelor of Science in microbiology and zoology.
      Gavin is a member of numerous professional and scientific societies, including the International AIDS Society and the American Association for the Study of Liver Disease. He also is a contributor to multiple editorial boards, including the Journal of Clinical Microbiology and Journal of Clinical Virology.

    Abstract

    DATE: May 15, 2019
    TIME: 9:00am PDT, 11:00am CDT, 12:00pm EDT

    Hepatitis B infections remain a significant global healthcare burden resulting in 887,000 deaths in 2015. Clinical laboratories can have a measurable impact in improving liver disease care while maximizing healthcare systems efficiencies through the application of high-quality diagnostic technologies. Abbott Laboratories legacy of innovation in hepatitis diagnostics spans decades and continues with the development of an automated assay for the detection of serum HBV pregenomic RNA (pgRNA). Serum HBV pgRNA has been proposed as a marker of HBV cccDNA activity and may be a useful clinical biomarker in evaluating chronic hepatitis B patient response to current nucleoside analogue therapy and aid in the development of novel therapeutic regimens. pgRNA kinetics in conjunction with other molecular and serologic tests may provide insights which aid in the staging and management of people with chronic HBV.

    Learning Objectives:

    • Understand the impact and healthcare burden of Global Hepatitis B Infections.
    • Discover how efforts in assay development led to pregenomicRNA (pgRNA) as an indicator of Hepatis B activity.
    • Comprehend the potential applications of pgRNA in therapy response monitoring.

     

    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

     


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    Loading Comments...
    Show Resources
    Attendees
    • See more